优化前列腺特异抗原密度临床相关截断值以对PI-RADS 3病灶患者进行风险分层
该回顾性队列研究纳入790例PI-RADS 3病灶患者,其中151例(19%)为临床有意义前列腺癌(csPCa)。CHAID分析显示PSAd是唯一显著影响因素,PSAd截断值0.13 ng/ml/cc时csPCa检出率为1% vs 18%,三节点模型截断值0.09和0.16 ng/ml/cc时检出率为0.5% vs 2% vs 17%。作者认为PSAd低于0.13尤其低于0.09者可省略前列腺穿刺。
要点
- PI-RADS 3病灶患者中csPCa检出率为19%(151/790)。
- PSAd是CHAID决策树中唯一显著影响因素。
- 作者认为PSAd低于0.13尤其低于0.09者可省略穿刺以避免过度诊断。
核心结论
- 对于前列腺mpMRI显示PI-RADS 3病灶且PSAd低于0.13、尤其低于0.09的患者,可省略前列腺穿刺,以避免不必要的穿刺和非csPCa的过度诊断。
研究设计与样本
- 回顾性识别2016年1月至2023年4月期间接受MRI及后续MRI靶向和系统穿刺的4841例连续患者,最终分析仅纳入PI-RADS 3病灶患者790例。
主要发现
- 790例PI-RADS 3病灶患者中151例(19%)为csPCa(ISUP分级组≥2)。
- 多因素logistic回归显示年龄(OR 1.1 [1.0-1.1];p=0.01)和PSAd(OR 1643 [2717-41,997];p<0.01)与csPCa显著相关。
- CHAID分析识别PSAd为影响决策树的唯一显著因素。
- 两节点模型PSAd截断值0.13 ng/ml/cc,csPCa检出率1% vs 18%。
- 三节点模型PSAd截断值0.09 ng/ml/cc和0.16 ng/ml/cc,csPCa检出率0.5% vs 2% vs 17%。
关键数值与推荐
- 两节点模型PSAd截断值0.13 ng/ml/cc,csPCa检出率1% vs 18%。
- 三节点模型PSAd截断值0.09 ng/ml/cc和0.16 ng/ml/cc,csPCa检出率0.5% vs 2% vs 17%。
临床怎么用
- 作者认为,对于前列腺mpMRI显示PI-RADS 3病灶且PSAd低于0.13、尤其低于0.09的患者,可省略前列腺穿刺。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate Imaging Reporting and Data System (PI-RADS) 3 lesions, identified through multiparametric magnetic resonance imaging (mpMRI), present a clinical challenge due to their equivocal nature in predicting clinically significant prostate cancer (csPCa). Aim of the study is to improve risk stratification of patients with PI-RADS 3 lesions and candidates for prostate biopsy. METHODS: A cohort of 4841 consecutive patients who underwent MRI and subsequent MRI-targeted and systematic biopsies between January 2016 and April 2023 were retrospectively identified from independent prospectively maintained database. Only patients who have PI-RADS 3 lesions were included in the final analysis. A multivariable logistic regression analysis was performed to identify covariables associated with csPCa defined as International Society of Urological Pathology (ISUP) grade group ≥2. Performance of the model was evaluated using the area under the receiver operating characteristic curve (AUC), calibration, and net benefit. Significant predictors were then selected for further exploration using a Chi-squared Automatic Interaction Detection (CHAID) analysis. RESULTS: Overall, 790 patients had PI-RADS 3 lesions and 151 (19%) had csPCa. Significant associations were observed for age (OR: 1.1 [1.0-1.1]; p = 0.01) and PSA density (OR: 1643 [2717-41,997]; p < 0.01). The CHAID analysis identified PSAd as the sole significant factor influencing the decision tree. Cut-offs for PSAd were 0.13 ng/ml/cc (csPCa detection rate of 1% vs. 18%) for the two-nodes model and 0.09 ng/ml/cc and 0.16 ng/ml/cc for the three-nodes model (csPCa detection rate of 0.5% vs. 2% vs. 17%). CONCLUSIONS: For individuals with PI-RADS 3 lesions on prostate mpMRI and a PSAd below 0.13, especially below 0.09, prostate biopsy can be omitted, in order to avoid unnecessary biopsy and overdiagnosis of non-csPCa.
引用
- Mjaess G, Haddad L, Jabbour T, et al. Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions. Prostate Cancer Prostatic Dis. 2024. PMID: 39048664. doi:10.1038/s41391-024-00872-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。